Autres langues Endo International plc

Actions

ENDPQ

IE00BJ3V9050

Temps Différé OTC Markets Autres places de cotation 20:20:16 23/04/2024			Varia. 5j.	Varia. 1 janv.
0,0006 ^USD	-14,29 %		-85,00 %	+20,00 %

19/03	Le fabricant de médicaments Endo reçoit l'approbation d'un tribunal américain pour la restructuration de sa faillite	RE
06/03	Endo International plc publie ses résultats pour l'exercice clos le 31 décembre 2023	CI

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Endo International plc - Par Pharmaceutical Issues Voluntary Nationwide Recall of Seven Lots of Treprostinil Injection Due to Potential for Silicone Particulates in the Product Solution	16:08
Endo, Inc. Announces Proposed New Senior Secured Credit Facilities	02/04
Endo Launches Ibuprofen-Famotidine Tablets, Generic Version of DUEXIS	27/03
Fourth Amended Joint Reorganization Plan Approved for Endo International plc	22/03
Health Care Down on Rate Bias -- Health Care Roundup	20/03
News Highlights : Top Company News of the Day - Wednesday at 5 PM ET	20/03
Drugmaker Endo receives US court approval for bankruptcy restructuring	19/03
Drugmaker Endo receives US court approval for bankruptcy restructuring, Bloomberg News reports	19/03
Fourth Amended Joint Reorganization Plan Filed by Endo International plc	18/03
Par Pharmaceutical Issues Voluntary Nationwide Recall of One Lot of Treprostinil Injection Due to Potential for Silicone Particulates in the Product Solution	12/03
North American Morning Briefing : Stock Futures -2-	11/03
Health Care Flat After Trial Setbacks -- Health Care Roundup	08/03
Endo International plc Reports Earnings Results for the Full Year Ended December 31, 2023	06/03
Endo International plc Reports Property, Plant and Equipment Impairment Charges for the Three Months Ended December 31, 2023	06/03
Endo International plc Provides Earnings Guidance for the Year 2024	06/03
Endo International plc Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	06/03
ENDO REPORTS FOURTH-QUARTER 2023 FINANCIAL RESULTS	06/03
Drugmaker Endo reaches $465 mln bankruptcy settlement with US	29/02
Endo Reaches Resolution with U.S. Department of Justice Regarding Legacy Marketing of Opana® ER	29/02
Third Amended Joint Reorganization Plan and Disclosure Statement Filed by Endo International plc	20/02

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Endo International plc

Actions

ENDPQ

IE00BJ3V9050

Autres langues

Filtres